Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26.

Slides:



Advertisements
Similar presentations
Eur Heart J 2013; 34:
Advertisements

Break the Fast: “Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control.
Lipoprotein Structure, Function, and Metabolism
New (U.S.) Lipid Guidelines (The Good and Bad) Robert A. Vogel, MD Clinical Professor of Medicine University of Colorado Denver Disclosures: National Coordinator.
Lipid Disorders and Management in Diabetes
European Heart Journal 2010; 31:
HDL Particles but not LDL Particles Predict Cardiovascular Disease Events in HIV Patients: Results from Strategies for Management of ART Study (SMART)
Lipids (Lipid Profile)
Lipoproteins Clusters of lipids associated with proteins that serve as transport vehicles for lipids in the lymph and blood.
Lipoproteins/Particles
Low level of high density lipoprotein cholesterol in children of patients with premature coronary heart disease. Relation to own and parental characteristics.
By: David Tran, Mercer University, 2013 Pharm.D. Candidate Prececptor: Dr. Ali Rahimi Morbidity and Mortality Associated with Dyslipidemia.
Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:
© Copyright 2009 by the American Association for Clinical Chemistry Nonfasting Lipids, Lipoproteins, and Apolipoproteins in Individuals With and Without.
Introduction Lipoprotein(a) [Lp(a)]
Lab. 8.  The major lipids present in the plasma are:  fatty acids,  Triglycerides,  cholesterol  and phospholipids.  Other lipid-soluble substances,
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer.
The Molecular and Clinical Heterogeneity of FH
An update on regional variation in cardiovascular mortality within Europe by Jacqueline Müller-Nordhorn, Sylvia Binting, Stephanie Roll, and Stefan N.
Lab 6 TC, LDL-C, HDL-C, and TG T.A. Bahiya Osrah
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Flaxseed in Pediatric Hyperlipidemia Wong H, Chahal N, Manlhiot C, Niedra E, McCrindle.
Lipid profiles in Cardio Vascular Diseases. What is a lipid profile? The lipid profile is a group of tests that are often ordered together to determine.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Lipid Profile, Plasma Apolipoproteins, and Risk of.
Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.
Upon entry into the circulation, chylomicrons (containing apo B-48) produced by the small intestine, and VLDL (containing apo B-100) produced by the liver.
The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Nonfasting Glucose, Ischemic Heart Disease, and.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Next Steps in Primary Prevention of Coronary Heart.
Date of download: 9/19/2016 From: Angiotensinogen Mutations and Risk for Ischemic Heart Disease, Myocardial Infarction, and Ischemic Cerebrovascular Disease:
Apolipoproteins as markers and managers of coronary risk by D.C. Chan, and G.F. Watts QJM Volume 99(5): April 24, 2006 © The Author Published.
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Figure 1: Questions included in questionnaire
M.Sc. in Pharmacy/Clinical Laboratory Sciences
Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from the Irish Longitudinal Study on Ageing.
Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular events [cardiovascular.
What Lipoprotein Related Parameters Should Be Measured And How Should They Be Treated in Dyslipidemic Patients with Cardiovascular Disease? Peter O Kwiterovich,
Copyright © 2007 American Medical Association. All rights reserved.
Update on Clinical Trials with Novel CETP Inhibitors to Raise HDL: Where are We Today? H. Bryan Brewer, Jr. Washington Cardiovascular Associates Washington.
Phenotype vs. Genotype: Defining Severe Familial Hypercholesterolemia
Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Louise Bowman & Martin Landray on.
Atherosclerosis, Plaque Imaging
HDL cholesterol and cardiovascular risk Epidemiological evidence
Copyright © 2012 American Medical Association. All rights reserved.
HDL cholesterol and cardiovascular risk
Jonathan Morrell Hastings
Oxford Niacin Trial.
Review of Cholesterol and Lipoproteins
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
Baseline characteristics of HPS participants by prior diabetes
The results of the SHARP trial
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report  Terry A. Jacobson, MD, Matthew K. Ito,
Type 2 diabetes: Overlap of clinical conditions
Jonathan C. Cohen, PhD  Journal of Clinical Lipidology 
Description of studies for pooled analyses
Kamstrup PR, et al. JAMA 2009; 301:
Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.
To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B?  Carl J. Lavie, MD, Richard V. Milani, MD, James.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
An example of the Lancet
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Take home figure The protective role of CNP/NPR-B/NPRC.
Ongoing statin therapy at hospitalization for acute myocardial infarction. Learnings for general practitioners. Ghena Shabana Specialist in Family Medicine.
Goals & Guidelines A summary of international guidelines for CHD
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Study Flow Diagram Thompson A, et al. JAMA 2008;299:
The results of the SHARP trial
PROSPER: trial design                                                                                                                                                                 
Figure 1 Patient selection.
Figure 1 Grant agencies and charitable foundations supporting Plan S.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Presentation transcript:

Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26

Apo A1 Triglycerides Cholesterol HDL Remnants LDL Lipoproteins HDL cholesterol Remnant cholesterol LDL cholesterol ApoB or non-HDL cholesterol Alternative Triglycerides Lipids Lp(a) total mass Lp(a) Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26

Lipids, lipoproteins, and apolipoproteins as part of standard and expanded lipid profiles. Børge G. Nordestgaard et al. Eur Heart J 2016;eurheartj.ehw152 © The Author Published by Oxford University Press on behalf of the European Society of Cardiology.

Nordestgaard 2016 Fasting Nonfasting Lipoprotein lipase Chylomicron Chylomicron remnant VLDL IDL LDL Triglycerides Cholesterol

Total cholesterol Triglycerides LDL cholesterol HDL cholesterol Non-HDL cholesterol Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26 Fasting time, hours Mean, mg/dL Children, N=12,744 US National Health and Nutrition Examination Survey

Mean concentrations of lipids and lipoproteins as a function of the fasting period following the last meal in children from the US general population. Børge G. Nordestgaard et al. Eur Heart J 2016;eurheartj.ehw152 © The Author Published by Oxford University Press on behalf of the European Society of Cardiology. US National Health and Nutrition Examination Survey

Total cholesterol Triglycerides LDL cholesterol HDL cholesterol Total cholesterol Triglycerides LDL cholesterol HDL cholesterol Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26 Calgary Laboratory Services in Canada

Mean concentrations of lipids and lipoproteins as a function of the period of fasting following the last meal in men and women from the Canadian general population. Børge G. Nordestgaard et al. Eur Heart J 2016;eurheartj.ehw152 © The Author Published by Oxford University Press on behalf of the European Society of Cardiology. Calgary Laboratory Services in Canada

N=92,285 Triglycerides Total cholesterol LDL cholesterol Remnant cholesterol NonHDL cholesterol Lipoprotein(a) Apolipoprotein B HDL cholesterol Apolipoprotein A No change mmol/Lmg/dL Decreased Maximal mean change after habitual food intake Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26 Copenhagen General Population Study

Maximal mean changes at 1–6 h after habitual food intake of lipids, lipoproteins, and apolipoproteins as part of standard and expanded lipid profiles in individuals in the Danish general population. Børge G. Nordestgaard et al. Eur Heart J 2016;eurheartj.ehw152 © The Author Published by Oxford University Press on behalf of the European Society of Cardiology. Copenhagen General Population Study

Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26

NonfastingFasting N= 5436 N= 470 R 2 = 0.84 MesLDL-C = 0.95 * calLDL-C R 2 = 0.87 MesLDL-C = 0.97 * calLDL-C Bias: -0.1 (95%CI: -0.9;0.6) Bias: -0.1 (95%CI: -0.8;0.6) Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26 Copenhagen City Heart Study

Comparison of calculated low-density lipoprotein cholesterol using the Friedewald equation with low-density lipoprotein cholesterol measured directly using random non-fasting and fasting lipid profiles. Børge G. Nordestgaard et al. Eur Heart J 2016;eurheartj.ehw152 © The Author Published by Oxford University Press on behalf of the European Society of Cardiology. Copenhagen City Heart Study

N=92, (1.23;1.53) 1.33(1.19;1.49) 1.45(1.29;1.62) 1.35(1.21;1.51) 1.57(1.41;1.75) 1.18(1.03;1.37) 1.60(1.43;1.78) 0.61(0.55;0.68) 0.72(0.65;0.80) 1.74(1.46;2.09) 1.78(1.50;2.11) 2.04(1.72;2.43) 1.71(1.43;2.05) 2.28(1.91;2.72) 1.62(1.33;2.01) 2.29(1.92;2.74) 0.49(0.41;0.59) 0.60(0.50;0.71) Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26 Copenhagen General Population Study

Risk of ischaemic heart disease and myocardial infarction for highest vs. lowest quintile of random non-fasting lipids, lipoproteins, and apolipoproteins as part of standard and expanded lipid profiles in individuals in the general population. Børge G. Nordestgaard et al. Eur Heart J 2016;eurheartj.ehw152 © The Author Published by Oxford University Press on behalf of the European Society of Cardiology. Copenhagen General Population Study

Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26

All > Diabetes No 4711 Yes 418 N TGs, mmol/L 5538 < Nonfasting Fasting Copenhagen hospital patients Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26

LDL cholesterol, mmol/L All > Diabetes No 4711 Yes 418 N Triglycerides, mmol/L 5538 < All > Diabetes No 3066 Yes 622 N LDL, mmol/L 4141 < Nonfasting Fasting Nonfasting Fasting Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26 Copenhagen hospital patients

Comparison of concentrations of plasma triglycerides and low-density lipoprotein cholesterol measured in the non-fasting and fasting states in the same patients. Børge G. Nordestgaard et al. Eur Heart J 2016;eurheartj.ehw152 © The Author Published by Oxford University Press on behalf of the European Society of Cardiology. Copenhagen hospital patients

Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26

Total cholesterol 72% Fraction of population 92,000 nonfasting samples from the Copenhagen General Population Study Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26

Total cholesterol 72% LDL cholesterol 60% Remnant cholesterol 27% Non-HDL cholesterol 50% HDL cholesterol 10% Triglycerides 27% Lipoprotein(a) 20% ApoB 59% Fraction of population ApoA1 9% Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26 Copenhagen General Population Study

Proportion of non-fasting individuals in the general population with flagged abnormal concentrations in laboratory reports using desirable concentration cut-points as shown in Table 5. Børge G. Nordestgaard et al. Eur Heart J 2016;eurheartj.ehw152 © The Author Published by Oxford University Press on behalf of the European Society of Cardiology. Copenhagen General Population Study

Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26

Separate referral to lipid specialist at Pancreatitis risk? HoFH? HeFH? Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26

 LDL  Remnant cholesterol  Nonfasting /fasting TG Chylo- microns  TG Nordestgaard 2015  CVD  Pancreatitis  CVD(  CVD)

Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26

Atherosclerosis Myocardial infarction Angina pectoris Elevated LDL cholesterol Mutations in LDL receptor, apolipoproteinB or PCSK9 Liver with only 50% functional LDL receptors Coronary heart disease Heterozygous familial hypercholesterolaemia Nordestgaard et al. EAS Consensus. Eur Heart J 2013; 34: (open access) LDLR>95% APOB2-5% PCSK9<1%

35yrs 53yrs 48yrs 55yr 12.5yrs Start high dose statin Start low dose statin Threshold for CHD Female sex Smoking Hypertension Diabetes  Triglycerides  HDL-C  Lipoprotein(a) Without FH Homozygous FHHeterozygous FH Age in years Coronary disease & death before age 20 Untreated coronary disease before age 55/60 Nordestgaard et al. EAS Consensus. Eur Heart J 2013; 34: (open access)

Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26

Lipoprotein(a) apolipo- protein(a) LDL-like particle Koschinsky et al. Cur Opin Lipidol 2004;15: KIV-2 copy number variant: 2 to >40 repeats

Lipoprotein(a) consists of an LDL-like particle to which apolipoprotein(a) is covalently linked. Nordestgaard B G et al. Eur Heart J 2010;31: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please

Copenhagen General Population Study Low number of Kringle IV-2 repeats High number of Kringle IV-2 repeats Nordestgaard 2010

Typical distributions of lipoprotein(a) levels in the general population. Nordestgaard B G et al. Eur Heart J 2010;31: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please Copenhagen General Population Study

Key university hospitals start using nonfasting lipid profiles National societies for cardiology, endocrinology, atheroslerosis, pediatrics, clinical chemistry, general practice and others adapt nonfasting lipid profiles Clinical chemistry laboratories no longer require fasting before lipid profile testing Journalists at key medias are invited to bring the story that fasting is no longer routinely required for lipid profile testing Key university hospitals start using desirable concentration cut-points to indicate abnormal concentrations as in Table 4 National societies for clinical chemistry, cardiology, endocrinology, atheroslerosis, pediatrics, general practice and other adapt desirable concentration cut-points Clinical chemistry laboratories use desirable concentration cut-points for lipid profile testing National societies enforce strategy Nonfasting lipid profilesLaboratory reporting on abnormal concentrations Implementation strategies in individual countries, states, and provinces for Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26

Suggested implementation strategies in individual countries, states, and/or provinces for use of non-fasting lipid profiles and for flagging in laboratory reports of abnormal values based on desirable concentration cut-points. Børge G. Nordestgaard et al. Eur Heart J 2016;eurheartj.ehw152 © The Author Published by Oxford University Press on behalf of the European Society of Cardiology.

Disclosures Supported by unrestricted educational grants to EAS and EFLM from Merck, Roche Diagnostics, and Denka Seiken. These companies were not present at the Joint Consensus Panel meetings, had no role in the design or content of the joint consensus statement, and had no right to approve or disapprove of the final document. Funding to pay the Open Access publication charges for this article was provided by the European Atherosclerosis Society and the European Federation of Clinical Chemistry and Laboratory Medicine. Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26